SNGX Stock Analysis: Buy, Sell, or Hold?
SNGX - Soligenix, Inc. Common Stock
$1.25
-0.06 (-4.58%)
▼
5d:
-9.42%
30d:
-6.02%
90d:
-20.38%
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 20, 2026
Get Alerted When SNGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SNGX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SNGX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SNGX is currently trading at $1.25, which is considered oversold relative to its 30-day fair value range of $1.33 to $1.43.
Technical Outlook: Technically, SNGX is in a downtrend. The price is currently testing key support at $1.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: SNGX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $17.50 (+1300.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SNGX is in a downtrend. The price is currently testing key support at $1.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: SNGX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $17.50 (+1300.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.33 -
$1.43
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 1300.0% below Wall St target ($17.50)
- CAUTION: 5-day price weakness (-9.4%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$1.33 -
$1.43
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.23
Resistance Level
$1.46
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.47
Wall Street Target
$17.50
(+1300.0%)
Revenue Growth (YoY)
-100.0%
Last updated: February 01, 2026 9:20 PM ET
Data refreshes hourly during market hours. Next update: 10:20 PM
Data refreshes hourly during market hours. Next update: 10:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNGX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Christopher J Schaber
BUY
15132 shares
2025-10-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
